HIGH OVERALL RESPONSE RATE WITH THE BTK INHIBITOR BGB‐3111 IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA: AN UPDATE ON SAFETY AND ACTIVITY. (June 2017) - Seymour, J.F.